← Back to patent-cliff list
雷贝拉唑钠
Tier C — Watch / tradeRabeprazole Sodium
卫材株式会社
Originator
1997
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：Proton pump
Brand：澳博平、波利特、Aciphex、Aciphex Sprinkle、瑞波特、Pariet、卡佩莱、奥加明、Aciphex/Pariet、Achipex、雨田青
Indications (approved)：胃食管反流病、消化性食管炎、十二指肠溃疡、胃溃疡、佐林格-埃利森综合征、胃灼痛、幽门螺杆菌感染、螺杆菌感染
Regional status
US
批准上市
1999-08-19
EU
终止
2008-02-01
China
批准上市
2000-02-03
Japan
批准上市
1997-10-14
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Rabeprazole Sodium?
Approved indications include: 胃食管反流病, 消化性食管炎, 十二指肠溃疡, 胃溃疡, 佐林格-埃利森综合征, 胃灼痛, 幽门螺杆菌感染, 螺杆菌感染.
When does the Rabeprazole Sodium patent expire?
No public expiry year is available for Rabeprazole Sodium yet; this page updates once verified.
How do I get a quote for Rabeprazole Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25